780

ANTI-TNF IN COMBINATION WITH LOW DOSE METHOTREXATE OUTPERFORMS ANTI-TNF MONOTHERAPY IN PATIENTS WITH PEDIATRIC CROHN'S DISEASE INITIATING ADALIMUMAB BUT NOT INFLIXIMAB

Date
May 8, 2023
Explore related products in the following collection:

There are no comments to view

Tracks

Related Products

Thumbnail for ANTIBIOTIC USE AMONG PEDIATRIC PATIENTS WITH PERIANAL COMPLICATIONS OF CROHN’S DISEASE IN A MULTICENTER COHORT: THE CASE FOR ANTIBIOTIC STEWARDSHIP
ANTIBIOTIC USE AMONG PEDIATRIC PATIENTS WITH PERIANAL COMPLICATIONS OF CROHN’S DISEASE IN A MULTICENTER COHORT: THE CASE FOR ANTIBIOTIC STEWARDSHIP
BACKGROUND: Perianal fistulizing complications (PFC) of Crohn’s disease (CD) are highly morbid and difficult to treat. Despite the advent of biologic medications, antibiotics remain a mainstay of PFC treatment…
Thumbnail for PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
PK, EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PEDIATRIC PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2 SHINE-1 STUDY
BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…
Thumbnail for TRAVEL TIME TO TREATING CENTER, BUT NOT RACE OR ETHNICITY IS ASSOCIATED WITH DIAGNOSTIC DELAY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
TRAVEL TIME TO TREATING CENTER, BUT NOT RACE OR ETHNICITY IS ASSOCIATED WITH DIAGNOSTIC DELAY IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
BACKGROUND: Perianal fistulizing complications (PFC) of Crohn’s disease (CD) are highly morbid and difficult to treat. Despite the advent of biologic medications, antibiotics remain a mainstay of PFC treatment…